Cloudbreak Pharma

Cloudbreak Pharma Inc. (2592.HK) is a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases, many of which have limited treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that are amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.